Literature DB >> 23134837

Antimicrobial catheters for reduction of symptomatic urinary tract infection in adults requiring short-term catheterisation in hospital: a multicentre randomised controlled trial.

Robert Pickard1, Thomas Lam, Graeme MacLennan, Kath Starr, Mary Kilonzo, Gladys McPherson, Katie Gillies, Alison McDonald, Katherine Walton, Brian Buckley, Cathryn Glazener, Charles Boachie, Jennifer Burr, John Norrie, Luke Vale, Adrian Grant, James N'Dow.   

Abstract

BACKGROUND: Catheter-associated urinary tract infection (CAUTI) is a major preventable cause of harm for patients in hospital. We aimed to establish whether short-term routine use of antimicrobial catheters reduced risk of CAUTI compared with standard polytetrafluoroethylene (PTFE) catheterisation.
METHODS: In our parallel, three group, multicentre, randomised controlled superiority trial, we enrolled adults (aged ≥16 years) requiring short-term (≤14 days) catheterisation at 24 hospitals in the UK. Participants were randomly allocated 1:1:1 with a remote computer allocation to receive a silver alloy-coated catheter, a nitrofural-impregnated catheter, or a PTFE-coated catheter (control group). Patients undergoing unplanned catheterisation were also included and consent for participation was obtained retrospectively. Participants and trial staff were unmasked to treatment assignment. Data were collected by trial staff and by patient-reported questionnaires for 6 weeks after randomisation. The primary outcome was incidence of symptomatic urinary tract infection for which an antibiotic was prescribed by 6 weeks. We postulated that a 3·3% absolute reduction in CAUTI would represent sufficient benefit to recommend routine use of antimicrobial catheters. This study is registered, number ISRCTN75198618.
FINDINGS: 708 (10%) of 7102 randomly allocated participants were not catheterised, did not confirm consent, or withdrew, and were not included in the primary analyses. Compared with 271 (12·6%) of 2144 participants in the control group, 263 (12·5%) of 2097 participants allocated a silver alloy catheter had the primary outcome (difference -0·1% [95% CI -2·4 to 2·2]), as did 228 (10·6%) of 2153 participants allocated a nitrofural catheter (-2·1% [-4·2 to 0·1]). Rates of catheter-related discomfort were higher in the nitrofural group than they were in the other groups.
INTERPRETATION: Silver alloy-coated catheters were not effective for reduction of incidence of symptomatic CAUTI. The reduction we noted in CAUTI associated with nitrofural-impregnated catheters was less than that regarded as clinically important. Routine use of antimicrobial-impregnated catheters is not supported by this trial. FUNDING: UK National Institute for Health Research Health Technology Assessment Programme.
Copyright © 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23134837     DOI: 10.1016/S0140-6736(12)61380-4

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  46 in total

Review 1.  [Urinary tract infections in the elderly].

Authors:  Klaus Friedrich Becher; Ingo Klempien; Andreas Wiedemann
Journal:  Z Gerontol Geriatr       Date:  2015-08-29       Impact factor: 1.281

Review 2.  The emerging threat of multidrug-resistant Gram-negative bacteria in urology.

Authors:  Hosam M Zowawi; Patrick N A Harris; Matthew J Roberts; Paul A Tambyah; Mark A Schembri; M Diletta Pezzani; Deborah A Williamson; David L Paterson
Journal:  Nat Rev Urol       Date:  2015-09-01       Impact factor: 14.432

3.  Safety and efficacy of a novel silver-impregnated urinary catheter system for preventing catheter-associated bacteriuria: a pilot randomized clinical trial.

Authors:  Anne-Marie Leuck; James R Johnson; Matthew A Hunt; Kush Dhody; Kazem Kazempour; Patricia Ferrieri; Susan Kline
Journal:  Am J Infect Control       Date:  2015-03-01       Impact factor: 2.918

Review 4.  Applying insights from biofilm biology to drug development - can a new approach be developed?

Authors:  Thomas Bjarnsholt; Oana Ciofu; Søren Molin; Michael Givskov; Niels Høiby
Journal:  Nat Rev Drug Discov       Date:  2013-10       Impact factor: 84.694

5.  Antimicrobial activity Study of triclosan-loaded WBPU on Proteus mirabilis in vitro.

Authors:  Ye Tian; Zhongyu Jian; Jianzhong Wang; Wei He; Qinyu Liu; Kunjie Wang; Hong Li; Hong Tan
Journal:  Int Urol Nephrol       Date:  2017-02-01       Impact factor: 2.370

6.  Bacteriophage-mediated control of a two-species biofilm formed by microorganisms causing catheter-associated urinary tract infections in an in vitro urinary catheter model.

Authors:  Susan M Lehman; Rodney M Donlan
Journal:  Antimicrob Agents Chemother       Date:  2014-12-08       Impact factor: 5.191

7.  Solidago, orthosiphon, birch and cranberry extracts can decrease microbial colonization and biofilm development in indwelling urinary catheter: a microbiologic and ultrastructural pilot study.

Authors:  Tommaso Cai; Iole Caola; Francesco Tessarolo; Federico Piccoli; Carolina D'Elia; Patrizio Caciagli; Giandomenico Nollo; Gianni Malossini; Gabriella Nesi; Sandra Mazzoli; Riccardo Bartoletti
Journal:  World J Urol       Date:  2013-10-04       Impact factor: 4.226

8.  Randomized controlled trial of silver-alloy-impregnated suprapubic catheters versus standard suprapubic catheters in assessing urinary tract infection rates in urogynecology patients.

Authors:  Ruchira Singh; Erik D Hokenstad; Sheila R Wiest; Shunaha Kim-Fine; Amy L Weaver; Michaela E McGree; Christopher J Klingele; Emanuel C Trabuco; John B Gebhart
Journal:  Int Urogynecol J       Date:  2018-08-25       Impact factor: 2.894

Review 9.  Pathophysiology, Treatment, and Prevention of Catheter-Associated Urinary Tract Infection.

Authors:  Ana Flores-Mireles; Teri N Hreha; David A Hunstad
Journal:  Top Spinal Cord Inj Rehabil       Date:  2019

10.  Irrigation with N,N-dichloro-2,2-dimethyltaurine (NVC-422) in a citrate buffer maintains urinary catheter patency in vitro and prevents encrustation by Proteus mirabilis.

Authors:  Suriani Abdul Rani; Chris Celeri; Ron Najafi; Keith Bley; Dmitri Debabov
Journal:  Urolithiasis       Date:  2015-08-18       Impact factor: 3.436

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.